Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
-
Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released
-
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
-
Newfoundland and Labrador Victims and Survivors of Alcohol and Drug-Related Crashes Remembered at MADD Canada’s Annual Memorial Monument Ceremony
-
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreati
-
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
-
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
-
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/
-
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
-
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
-
Blazpay’s Phase 2 of Crypto Presale Surges With Over $250,000 Raised as XRP and Bitcoin Consolidate
-
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Onco
-
General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025
-
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
-
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
-
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
-
Piazza Garibaldi Introduces End-to-End Project Management for Ultra-Luxury Living and Yachting
-
Westhaven Gold Provides Corporate Update
-
Aeroméxico Announces Filing of Amended Registration Statement for Proposed Global Offering
-
rYojbaba Expands Core Consulting and Health Services Business Internationally Through Partnerships with Koyamada International Foundation and Guardian Girls International
-
StoneX Expands Wealth Management Offering for Latin American Clients
-
Forum Ventures Bets Big on Category-Defining Vertical AI Solution for Healthcare Growth, Salubrum
-
The Canine Project Unveils Exclusive Dog Skincare Bundle for the Holidays
-
Her Agenda and the Ad Council Promote “Pretirement” Awareness with Stacked: Saving, Planning, and Playing with Intention
-
United Lithium Announces LOI to Acquire Uranium and Rare Earth Explorer Swedish Minerals AB, Creating a Diversified Nordic Strategic Metals Platform and Financing
-
Cleanfarms Brings Unwanted Pesticides & Old Livestock Medications Collection to Newfoundland, and Adds Recycling for Small Containers This October
-
Peanut Trade, Protocol Labs & Supermoon’s Startup Day at Token2049 Singapore Showcased leading Startups and VCs
-
Peanut Trade, Protocol Labs & Supermoon’s Startup Day at Token2049 Singapore Showcased leading Startups and VCs
-
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value As of September 2025
-
UniFirst Announces Revised Segment Reporting
-
FlexShopper, Inc. Announces Receipt of Delisting Notification from Nasdaq
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Industry Leaders Join Ingenio Care’s Mission to Redefine Access, Coordination, and Value in U.S. Healthcare
-
Mawson Finland Highlights Closing of First Nordic’s $80M Financing, Announces Date of Special Shareholder Meeting for Arrangement Approval, Announces Loan
-
Methode Electronics’ Board Approves Dividend
-
Volatus Aerospace to Attend the 2025 Maxim Growth Summit
-
Fury Files Technical Report for the Eau Claire Gold Project in Quebec
-
MPChat Publishes "The Fourth Covenant" Manifesto to Redefine Digital Freedom with Integrated Crypto Communication and Payment Tools
-
PyroGenesis Announces Repricing and Extension to Term of Warrants
-
CCH Holdings Ltd Announces Full Exercise of Over-Allotment Option
-
Univest Securities, LLC Announces Closing of $25 Million Registered Direct Offering for its Client UTime Limited (NASDAQ: WTO)
-
FAIRCHILD GOLD ANNOUNCES CLOSING OF PRIVATE PLACEMENT FINANCING
-
Rackspace Technology to Announce Third Quarter 2025 Earnings on November 6th, 2025
-
Rivalry Closes Second Tranche of Private Placement
-
Onex Canada Asset Management Inc. Announces Termination of Onex Global Equity Fund
-
SKK HOLDINGS LIMITED ANNOUNCES RECEIPT OF NASDAQ EXTENSION OF COMPLIANCE PERIOD REGARDING MINIMUM PRICE DEFICIENCY
-
Gyrodyne Announces Agreement with Star Equity Fund
-
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
-
Credicorp Ltd.: Credicorp’s “3Q25 quiet period”
-
SplitVue Introduces Dual-Screen Monitor Focused on Ergonomic Design and Workplace Efficiency
